There remain significant unmet needs in rheumatoid arthritis. Overcome your pain points with an experienced and trusted partner.

1. RHEUMATOID ARTHRITIS
TREATMENT LANDSCAPE
Overcome Your Pain Points With an
Experienced and Trusted Partner
RA DRUG DEVELOPMENT PAIN POINTS
 Crowded trial environment causes competition for sites, longer recruitment windows
and difficulty in identifying investigators and locating patients
 Only 10% of RA patients participate in clinical trials
 Difficulty maintaining data quality due to eligibility creep and subjective trial endpoints
 Suboptimal patient retention over long trial periods
 Competitive biologics marketplace
 Increases in trial complexity exacerbates recruitment and retention challenges
COVANCE IS EXPERIENCED IN OVERCOMING
RA CLINICAL TRIAL CHALLENGES
 1200 experienced RA staff including 558 clinical research associates
and 148 project managers
 Supported over 60 RA trials in the past five years, including
>2,200 sites and >12,300 patients
 Helped develop 14 of the 15 top IMID drugs, of which a number
are indicated in rheumatic conditions
THERE REMAINS SIGNIFICANT UNMET NEED IN RA
Biologic administration
is often inconvenient
and expensive
Safety of RA treatments,
particularly immunosuppressive
drugs, is still a concern
There is
no cure
RA INDUSTRY UPDATES
Increasing availability of biosimilars making biologic treatments more accessible
Biosimilars to infliximab, etanercept and adalimumab all approved
A trend towards more aggressive treatment under the
"treat to target" strategy
Steady market
growth due in
part to aging
population
Movement towards
early diagnosis
and treatment of patients
Expanded range of treatment
options including novel biologics
and small molecules

2. COVANCE DRUG
DEVELOPMENT SOLUTIONS
Addressing the Pain Points of
RA Drug Development
 Reduce screen failure rate using Xcellerate®
Trial Design to understand
impact of inclusion criteria on size of eligible patient population
 Clinical trial opt-in patient initiative* currently with >2,572 RA patients
 Performance metrics on >1,400 Ph II–III RA investigators since 2012
 All RA study recruitment timelines achieved since 2012
 Specialty inflammatory biomarkers, e.g., GlycA, rheumatoid factor and hCRP
OPTIMIZE STUDY PLANNING AND FEASIBILITY, AND SPEED
PATIENT ENROLLMENT BY LEVERAGING OUR UNIQUE DATA SETS
Clinical knowledgebase with historical investigator performance data
housing >40% global clinical trial data at any one time
TARGET PATIENT POPULATIONS FOR EFFICIENT RECRUITMENT
IMPROVE PATIENT RETENTION THROUGH EDUCATION AND SUPPORT
 Established patient support system, including health education
and appointment reminders
 Covance voice of patient insights used in trial design to ensure
compliance and retention
*Database of patients that have agreed to be contacted directly about relevant clinical trials (November 2017)
Learn more about our drug development solutions at www.covance.com
Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory
Corporation of America Holdings (LabCorp). COVANCE is registered trademark and the
marketing name for Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe / Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2018 Covance Inc. INFCDS004-0118
Total of >200,000
unique clinical investigators
Total of >15 billion
lab test results
Total of >793,000
physicians
Total of >14 million
patient clinical trial visits
Total of >16,000
protocols
Total of >142 million
patients since 2011